ECM
APLS

ExodusPoint Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

ExodusPoint Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
+6,800
New +$147K ﹤0.01% 1332

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ExodusPoint Capital Management's APLS Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Apellis Pharmaceuticals (APLS) stake by 63% in Q1 2026, selling an estimated $2.33M and leaving 62,989 shares worth $2.53M. The position accounts for 0.02% of the portfolio, ranked #677.

ExodusPoint Capital Management first reported a position in APLS in Q3 2020 and has held it in 12 quarters since. The position peaked at $5.48M in Q1 2025. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • ExodusPoint Capital Management held 62,989 shares of Apellis Pharmaceuticals worth $2.53M as of Q1 2026.
  • ExodusPoint Capital Management sold 108,167 Apellis Pharmaceuticals shares in Q1 2026, an estimated $2.33M.
  • Apellis Pharmaceuticals made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #677 holding.
  • ExodusPoint Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2020 and has held it in 12 quarters since.
  • ExodusPoint Capital Management's Apellis Pharmaceuticals position peaked at $5.48M in Q1 2025.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.